Site icon pharmaceutical daily

FDA issues three warning letters to companies dealing with cannabis related products

A view shows the U.S. Food and Drug Administration (FDA) headquarters in Silver Spring, Maryland August 14, 2012. REUTERS/Jason Reed/File Photo

In a statement from the US FDA commissioner, the FDA on Tuesday said it has issued warning letters, in collaboration with the Federal Trade Commission, to three companies – Advanced Spine and Pain LLC (d/b/a Relievus)Nutra Pure LLC and PotNetwork Holdings Inc. – in response to their making unsubstantiated claims related to more than a dozen different products and spanning multiple product webpages, online stores and social media websites.

According to FDA’s press release, the companies used these online platforms to make unfounded, egregious claims about their products’ ability to limit, treat or cure cancer, neurodegenerative conditions, autoimmune diseases, opioid use disorder, and other serious diseases, without sufficient evidence and the legally required FDA approval.

Examples of claims made by these companies include:

FDA Commissioner Scott Gottlieb, said he believes these are egregious, over-the-line claims and that the FDA won’t tolerate this kind of deceptive marketing to vulnerable patients.

The press release was issued on new steps to advance agency’s continued evaluation of potential regulatory pathways for cannabis-containing and cannabis-derived products.

Exit mobile version